We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
“We believe in the value of science behind Eliquis and its therapeutic potential for patients, and the underlying intellectual property protecting these innovations,” the companies said in a joint statement. Read More
Heather Bresch — daughter of U.S. Sen. Joe Manchin (D-W.V.) and former CEO of Mylan — allegedly played a key role in squelching both a competing epinephrine self-injector and single-dose EpiPens, leaving pricey two-dose brand-name packs as patients’ only options, newly released court documents are claiming. Read More
Sanofi has dropped $1.9 billion to acquire New York-based Kadmon Pharmaceuticals and its first-in-class oral kinase inhibitor, Rezurock (belumosudil), approved in July to treat chronic graft-vs.-host disease (cGVHD). Read More
Roche has partnered with UK-based Adaptimmune Therapeutics to develop “off-the-shelf” T-cell therapies for up to five cancer targets in a deal valued at $150 million upfront but potentially worth up to $3 billion to the UK company. Read More
The FDA approved Aduhelm in early June, despite the drug showing only moderate benefit in one phase 3 trial and no benefit in another late-stage study. Read More
The co-founders of Taiwan-based JHL Biotech have pleaded guilty in a federal court of stealing trade secrets from Roche’s subsidiary Genentech. Read More
The companies will use Lycia’s lysosomal targeting chimera platform to develop new medicines for as many as five protein targets across different Lilly research areas. Read More
A federal appeals court has reversed a $1.2 billion ruling which found Gilead Sciences’ cancer immunotherapy Yescarta (axicabtagene ciloleucel) infringed on a Bristol Myers Squibb (BMS) patent for CAR-T technology. Read More